The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathogenetic studies have shown that Aβ peptide accumulation in the brain is an early and central event, 2”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [2]
In the citing paper
“One possible resolution is that amyloid pathology acts only as a trigger in sporadic AD (Karran et al., 2011); i.e., Aβ accumulation is necessary but insufficient to cause full-blown disease.”
From The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques (2019) · cites this paper as Karran et al., 2011
In the citing paper
“since it is known that the Aβ plaques act as a driver of AD pathology63 and the accumulation Aβ plaques in the brain initiates a complex multicellular neurodegenerative process.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [63]
In the citing paper
“The amyloid cascade hypothesis, which dominated the field for over three decades, proposed that the abnormal accumulation of Aβ initiates a downstream cascade leading to tau hyperphosphorylation, synaptic dysfunction, and neuronal death [6, 7].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [7]
In the citing paper
“a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Karran et al., 2011
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“The apolipoprotein E ( APOE ) gene represents the major genetic risk factor for A”
BackgroundAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“The discovery that AD could be inherited in an autosomal dominant fashio”
Background
Research works printed but not linked: 2
- Burns, A. & Ilife, S. Dementia. BMJ 338, 405–409 (2009).
- Alzheimer, A. About a peculiar disease of the cerebral cortex. [in German] Centralblatt für Nervenheilkunde Psychiatrie 30, 177–179 (1907).
Cited by
Items 901–1,000 of 1,007
Wei, M., Liu, Y., Pi, Z., Li, S., Hu, M., He, Y., Yue, K., Liu, T., Liu, Z., Song, F., et al. (2019) · Molecules · doi:10.3390/molecules24071203 · Cited by 31
“A widely accepted hypothesis is the amyloid cascade hypothesis, which suggests that amyloid beta (Aβ) deposition might trigger neuronal dysfunction and death in the brain, resulting in AD [3].”
BackgroundMetabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers
Elfgen, A., Hupert, M., Bochinsky, K., Tusche, M., Román, E. G. D. S., Gering, I., Sacchi, S., Pollegioni, L., Huesgen, P. F., Hartmann, R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41993-6 · Cited by 29
Rawat, K., Tewari, D., Bisht, A., Chandra, S., Tiruneh, Y. K., Hassan, H. M., Al‐Emam, A., Sindi, E. R., & Al-Dies, A.-A. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-81285-2 · Cited by 38
Effect of the Aβ Aggregation Modulator MRZ-99030 on Retinal Damage in an Animal Model of Glaucoma
Salt, T. E., Nizari, S., Cordeiro, M. F., Russ, H., & Danysz, W. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9488-6 · Cited by 29
“Amyloid-b (Ab) is the major constituent of senile plaques in Alzheimer’s disease (AD), the formation of which, caused by abnormal processing of amyloid precursor protein (APP), has been implicated in AD neuropathology (Karran et al. 2011; Mattson et al. 1993).”
BackgroundOvercoming translational barriers impeding development of Alzheimer's disease modifying therapies
Golde, T. E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13583 · Cited by 29
“There are many opinions as to why recent trials have failed, which have been extensively reviewed (Golde et al. 2011b; Karran et al. 2011; Cummings et al. 2014; De Strooper and Chavez Gutierrez 2015; Toyn 2015).”
BackgroundVibration-Induced-Emission (VIE) for imaging amyloid β fibrils
Dou, W., Chen, W., He, X., Su, J., & Tian, H. (2016) · Faraday Discussions · doi:10.1039/c6fd00156d · Cited by 28
de Almeida, N. E. C., Do, T. D., LaPointe, N. E., Jhatro, M., Feinstein, S. C., Shea, J., & Bowers, M. T. (2016) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2016.09.018 · Cited by 33
“The nanoESI-Q mass spectrum of pure Aβ1-40 (Figure 1A) reveals the presence of two major peaks at m/z 1081 and 1442, corresponding to Aβ monomers: [n]z = [1]−4 and [1]−3, respectively, where n is the oligomer number and z the charge.”
BackgroundInfluentialShuaib, S., Saini, R. K., Goyal, D., & Goyal, B. (2017) · ChemistrySelect · doi:10.1002/slct.201601970 · Cited by 29
Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer’s disease
Schirinzi, T., Lazzaro, G. D., Sancesario, G. M., Colona, V. L., Scaricamazza, E., Mercuri, N. B., Martorana, A., & Sancesario, G. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1786-8 · Cited by 33
“…(BBB) into the peripheral circulation, an amount is alternatively removed by means a system of interstitial fluid (ISF)–CSF interchange, named ‘‘glymphatic system’’, sustained by the fluids bulk flow and, thus, strictly dependent on the CSF pressure (Karran et al. 2011; Simon and Iliff 2016).”
BackgroundMeng, L., Li, B., Li, D.-N., Wang, Y., Lin, Y., Meng, X., Sun, X., & Liu, N. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.09.025 · Cited by 28
Robinson, M. J., Turnbull, S., Lee, B. Y., & Leonenko, Z. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183363 · Cited by 32
Zhang, Y., Ding, C., Li, C., & Wang, X. (2021) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.08.008 · Cited by 29
Glycoengineering artificial receptors for microglia to phagocytose Aβ aggregates
Yu, D., Liu, C., Zhang, H., Ren, J., & Qu, X. (2021) · Chemical Science · doi:10.1039/d0sc07067j · Cited by 29
Rani, A., Singh, A., Kaur, J., Singh, G., Bhatti, R., Gumede, N. J., Kisten, P., Singh, P., Sumanjit, & Kumar, V. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105053 · Cited by 31
Experimental evidence for temporal uncoupling of brain Aβ deposition and neurodegenerative sequelae
Rother, C., Uhlmann, R. E., Müller, S. A., Schelle, J., Skodras, A., Obermüller, U., Häsler, L. M., Lambert, M., Baumann, F., Xu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34538-5 · Cited by 28
Portelius, E., Hölttä, M., Soininen, H. S., Bjerke, M., Zetterberg, H., Westerlund, A., Herukka, S., Blennow, K., & Mattsson, N. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8302-1 · Cited by 29
“This is consistent with biomarker results from patients with other types of autosomal domi- nant early onset AD where the disease is believed to be caused by Ab overproduction or an increase in the Ab1-42/ Ab1-40 ratio (Karran et al. 2011; Reiman et al. 2012).”
Borghys, H., Broeck, B. V., Dhuyvetter, D., Jacobs, T., Waepenaert, K. D., Erkens, T., Brooks, M., Thevarkunnel, S., & Araujo, J. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160434 · Cited by 33
HERBAL MEDICINES AS NEUROPROTECTIVE AGENT: A MECHANISTIC APPROACH
Roy, S., & Awasthi, H. (2017) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2017v9i11.19444 · Cited by 36
Pharmacological Treatment of Alzheimer’s Disease: Insights from Drosophila melanogaster
Cheng, X., Song, C., Du, Y., Gaur, U., & Yang, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134621 · Cited by 32
“Most of the recent studies on AD have been primarily focused on β-amyloid (Aβ) and Tau protein [5-8].”
BackgroundFonseca‐Gomes, J., Costa-Coelho, T., Ferreira-Manso, M., Inteiro-Oliveira, S., Vaz, S. H., Alemãn-Serrano, N., Atalaia-Barbacena, H., Ribeiro‐Rodrigues, L., Ramalho, R. M., Pinto, R. R., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.022 · Cited by 28
Panza, F., Dibello, V., Sardone, R., Zupo, R., Castellana, F., Leccisotti, I., Moretti, M. C., Altamura, M., Bellomo, A., Daniele, A., et al. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2463963 · Cited by 30
“Following disappointing anti-Aβ RCTs, Karran and colleagues suggested four ‘disease sce-narios’ when interpreting the role of Aβ in the AD neurode-generation: as ‘irrelevant’ or an innocent ‘bystander,’ a ‘driver’ mechanism, a ‘threshold’ mechanism, or ‘trigger’ [18].”
Ramachandran, U., Manavalan, A., Sundaramurthi, H., Sze, S. K., Feng, Z. W., Hu, J., & Heese, K. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.03.012 · Cited by 27
“Since currently no effective therapy is in place for the treatment of such diseases, recent data predict that the number of people affected by AD and aging-related dementia will continue to grow at an epidemic pace (Both et al., 2011; Chiu and Rao, 2011; Heese et al., 2006; Karran et al., 2011).”
Fibril formation and toxicity of the non-amyloidogenic rat amylin peptide
Milton, N. G. N., & Harris, J. R. (2012) · Micron · doi:10.1016/j.micron.2012.07.001 · Cited by 29
“Human amylin fibrils have been shown o be cytotoxic to a number of cell types (Kawahara et al., 2000; itzel et al., 2007).”
BackgroundTosun, D., Chen, Y.-F., Yu, P., Sundell, K. L., Suhy, J., Siemers, E., Schwarz, A. J., Weiner, M. W., & Initiative, A. D. N. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.009 · Cited by 27
“The “A b hypothesis” [35,36] posits that accumulation of A b is primarily responsible for the accumulation of tau tangles, synaptic dysfunction, neurodegeneration, and cognitive decline especially in memory function, which characterizes AD.”
Genesis of Neuroprotective Peptoid from Aβ30–34 Inhibits Aβ Aggregation and AChE Activity
Pradhan, K., Das, G., Mondal, P., Khan, J., Barman, S., & Ghosh, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00071 · Cited by 27
Pradhan, K., Das, G., Gupta, V., Mondal, P., Barman, S., Khan, J., & Ghosh, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00427 · Cited by 27
Sedighi, M., Baluchnejadmojarad, T., Afshin‐Majd, S., Amiri, M., Aminzade, M., & Roghani, M. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01621-9 · Cited by 32
Morales-Zavala, F., Jara-Guajardo, P., Chamorro, D., Riveros, A. L., Chandía-Cristi, A., Salgado, N., Pismante, P., Giralt, E., Sánchez‐Navarro, M., Araya, E., et al. (2021) · Biomaterials Science · doi:10.1039/d0bm01825b · Cited by 26
The Current Landscape of Prevention Trials in Dementia
Lee, J., Howard, R. S., & Schneider, L. S. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01236-5 · Cited by 31
“Of those that did, we are not aware of any that showed success in phase 2 and 3 clinical trials on its primary outcome [3].”
BackgroundMulti-Target-Directed Cinnamic Acid Hybrids Targeting Alzheimer’s Disease
Drakontaeidi, A., & Pontiki, E. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010582 · Cited by 32
Mechanism of Nucleation and Growth of Aβ40 Fibrils from All-Atom and Coarse-Grained Simulations
Sasmal, S., Schwierz, N., & Head-Gordon, T. L. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b09655 · Cited by 27
“(1) For the first monomer ensemble, referred to as the Fibril ensemble, we have used individual monomers derived from the middle cross-sections of protofibrils equilibrated with the coarse-grain potentials.”
MethodA short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 29
“The duration of treatment for sustained beneficial effect is likely to be life long as the longitudinal data suggest that amyloid deposition is probably the triggering event for AD rather than necessary throughout the disease (Karran et al., 2011).”
BackgroundWang, H., Xiao, L., Wang, G., & Wang, G. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.112749 · Cited by 29
Parthsarathy, V., McClean, P. L., Hölscher, C., Taylor, M., Tinker, C. L., Jones, G., Kolosov, O., Salvati, E., Gregori, M., Masserini, M., et al. (2013) · PLoS ONE · doi:10.1371/annotation/57e0a947-8600-4658-b04c-cf7a45c8bd8d · Cited by 27
Strooper, B. D., & Voet, T. (2012) · Nature · doi:10.1038/488038a · Cited by 29
Self-citationXu, L., Shan, S., & Wang, X. (2013) · Journal of Physical Chemistry B · doi:10.1021/jp403288b · Cited by 24
Toyn, J. H., Boy, K. M., Raybon, J. J., Meredith, J. E., Robertson, A. S., Guss, V. L., Hoque, N., Sweeney, F., Zhuo, X., Clarke, W., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232249 · Cited by 27
“Direct pharmacological targets include the proteolytic enzymes, amyloid-b precursor protein cleaving enzyme and g-secretase, responsible for Ab production by cleavage of the amyloid-b precursor protein (APP; Karran et al., 2011), and Ab itself using anti-Ab antibodies (Karran, 2012).”
BackgroundTramutola, A., Abate, G., Lanzillotta, C., Triani, F., Barone, E., Iavarone, F., Vincenzoni, F., Castagnola, M., Marziano, M., Memo, M., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.414 · Cited by 26
Qin, Q., & Li, Y. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25481 · Cited by 27
Fish oil protects the blood–brain barrier integrity in a mouse model of Alzheimer’s disease
Xie, Y., Yan, L., Zeng, H., Chen, W., Lu, J., Wan, J., Su, H., & Yao, X. (2020) · Chinese Medicine · doi:10.1186/s13020-020-00314-0 · Cited by 26
Elizalde-Velázquez, G. A., Gómez‐Oliván, L. M., Rosales-Pérez, K. E., Orozco-Hernández, J. M., García-Medina, S., Islas‐Flores, H., & Galar‐Martínez, M. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.153095 · Cited by 27
Pang, M., Zhu, L., Gabelle, A., Gafson, A., Platt, R. W., Galvin, J. E., Krolak‐Salmon, P., Rubino, I., de Moor, C., Belachew, S. M., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12768 · Cited by 33
Hsieh, Y., Negri, J. M., He, A., Pearse, R. V., Liu, L., Duong, D. M., Chibnik, L. B., Bennett, D. A., Seyfried, N. T., & Young‐Pearse, T. L. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00558-4 · Cited by 27
“cascade of excessive tau phosphorylation and the formation of NFTs, reduction in synapses, and neurodegeneration [2, 3].”
BackgroundReekes, T. H., Ledbetter, C. R., Alexander, J., Stokes, K. Y., Pardue, S., Bhuiyan, M. A. N., Patterson, J. C., Lofton, K. T., Kevil, C. G., & Disbrow, E. A. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102633 · Cited by 26
Høilund‐Carlsen, P. F., Revheim, M.-E. R., Costa, T., Kepp, K. P., Castellani, R. J., Perry, G. L., Alavi, A. A., & Barrio, J. R. (2023) · Diagnostics · doi:10.3390/diagnostics13132254 · Cited by 30
“The amyloid cascade hypothesis postulates that Alzheimer’s disease (AD) is caused by cerebral deposits of the protein amyloid-beta (Aβ) [1,2].”
BackgroundAnti-amyloid: An antibody to cure Alzheimer’s or an attitude
Osborne, O., Naranjo, O., Heckmann, B. L., Dykxhoorn, D. M., & Toborek, M. J. (2023) · iScience · doi:10.1016/j.isci.2023.107461 · Cited by 26
“This hypothesis – termed the amyloid hypothesis – has dominated the scientific viewpoint on AD pathogenesis and therapeutic development for the past century.(3) While a significant portion of research and clinical trials have focused on targeting amyloid and APP proteins, the full scope of their roles in disease patho…”
BackgroundIn vivo optical signatures of neuronal death in a mouse model of Alzheimer's disease
Lin, A. J., Castello, N. A., Lee, G., Green, K. N., Durkin, A. J., Choi, B., LaFerla, F. M., & Tromberg, B. J. (2013) · Lasers in Surgery and Medicine · doi:10.1002/lsm.22206 · Cited by 25
“, memory loss) appear, the disease is so advanced that reversing or slowing the process is largely ineffective [2].”
BackgroundGuzmán, E. A., Bouter, Y., Richard, B. C., Lannfelt, L., Ingelsson, M., Paetau, A. E., Verkkoniemi‐Ahola, A., Wirths, O., & Bayer, T. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-13 · Cited by 33
“combined activity of β- and γ-secretase activities releases Aβ peptides of various lengths [5].”
BackgroundCyclodextrin Nanoparticles Bearing 8‐Hydroxyquinoline Ligands as Multifunctional Biomaterials
Oliveri, V., Bellia, F., & Vecchio, G. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201700031 · Cited by 27
Simvastatin ameliorates memory impairment and neurotoxicity in streptozotocin-induced diabetic mice
Fang, S., Xie, H., Fang, C., Hu, M. Y., Long, Y., Sun, H., Kong, L., Hong, H., & Tang, S. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.05.001 · Cited by 32
“Simvastatin is the most lipophilic drug in its class, and able to cross the blood brain barrier (BBB) (Ghosh et al., 2009), yet it exerts important immunomodulatory and anti-inflammatory effects independent of lowering lipids (Roy and Pahan, 2011; Krauss et al., 2013).”
Han, F., Zhuang, T.-T., Chen, J., Zhu, X.-L., Cai, Y., & Lu, Y.-P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185102 · Cited by 27
Wang, W., Liu, C., He, D., Shi, G., Song, P., Zhang, B., Tian, L., Wei, J., Jiang, Y., & Ma, L. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107189 · Cited by 29
Jia, L., Chen, Y., Li, H., Zhao, K., Ge, S., Wang, C., Zhao, J., Li, F., Zhang, L., & Yao, A. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02203-9 · Cited by 29
“The GS maintains CNS homeostasis by facilitating CSF–ISF exchange and clearing metabolic waste and inflammatory mediators [173, 174], positioning it as a central regulatory hub across pathologies.”
Guillot, F., Kemppainen, S., Lavasseur, G., Miettinen, P. O., Laroche, S., Tanila, H., & Davis, S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150926 · Cited by 26
“More damaging to the theory are results from clinical trials using compounds to reduce production or aggregation of amyloid, or to clear existing plaques from the brain, that have had a very poor success rate in improving cognitive performance (see [8, 9]).”
Simpson, L. W., Szeto, G. L., Boukari, H., Good, T. A., & Leach, J. B. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.05.030 · Cited by 25
The amyloid cascade hypothesis and Alzheimer’s disease: A mathematical model
Bertsch, M., Franchi, B., Meacci, L., Primicerio, M., & Tesi, M. C. (2020) · European Journal of Applied Mathematics · doi:10.1017/s0956792520000339 · Cited by 25
“accepted, Aβ amyloid plays an important role in the process of the cerebral damage (the socalled amyloid cascade hypothesis [39]).”
BackgroundProbing Mechanisms and Therapeutic Potential of γ-Secretase in Alzheimer’s Disease
Wolfe, M. S. (2021) · Molecules · doi:10.3390/molecules26020388 · Cited by 28
“As mentioned above, the “amyloid hypothesis” of AD pathogenesis has reigned for decades, and AD drug development has largely focused on inhibiting Aβ production, blocking Aβ aggregation, or facilitating Aβ clearance from the brain [6].”
BackgroundChiang, T.-I., Yu, Y., Lin, C., & Lane, H. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.3.423 · Cited by 27
Microglial Endocannabinoid Signalling in AD
Scipioni, L., Ciaramellano, F., Carnicelli, V., Leuti, A., Lizzi, A. R., Dominicis, N. D., Oddi, S., & Maccarrone, M. (2022) · Cells · doi:10.3390/cells11071237 · Cited by 29
“which represent pathognomonic signs of AD: (i) amyloid-β (Aβ) oligomers and polymers build up in the brain of affected people and constitute the typical plaques that are considered the main cause of neuronal loss and toxicity [44]; (ii) tau, a protein involved in stabilizing the microtubules and controlling axonal tra…”
BackgroundSajad, M., Kumar, R., & Thakur, S. C. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.04.009 · Cited by 28
“Transgenic mice expressing variants of APP or presenilin protein carrying human familial AD-associated mutations have increasingly developed Aβ plaques and memory defects in the brain, additionally strengthening the principle that the accumulation of Aβ can cause AD (Karran et al., 2011).”
BackgroundElizalde-Velázquez, G. A., Gómez‐Oliván, L. M., García-Medina, S., Rosales-Pérez, K. E., Orozco-Hernández, J. M., Islas‐Flores, H., Galar‐Martínez, M., & Hernández‐Navarro, M. D. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.157888 · Cited by 25
Unveiling the Potential of Polyphenols as Anti-Amyloid Molecules in Alzheimer’s Disease
Kabir, E. R., Chowdhury, N. M., Yasmin, H., Kabir, M. T., Akter, R., Perveen, A., Ashraf, G. M., Akter, S., Rahman, M. H., & Sweilam, S. H. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666221010113812 · Cited by 26
“As per this hypothesis, Aβ deposition into plaques in brain tissues is the major causative factor of AD [2].”
BackgroundMetal Chaperones: A Holistic Approach to the Treatment of Alzheimer’s Disease
Adlard, P. A., & Bush, A. I. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00015 · Cited by 26
“These have formed the basis for several commentaries (Karran et al., 2011; Sperling et al., 2011) on the state of AD clinical trials and therapeutics, and will not be discussed here.”
Sonawane, K. D., & Barage, S. H. (2014) · Amino Acids · doi:10.1007/s00726-014-1887-8 · Cited by 25
Fissers, J., Waldron, A., Vijlder, T. D., Broeck, B. V., Pemberton, D. J., Mercken, M. H., der Veken, P. V., Joossens, J., Augustyns, K., Dedeurwaerdere, S., et al. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0935-z · Cited by 28
Self-citationNasaruddin, M. L., Pan, X., McGuinness, B., Passmore, P., Kehoe, P. G., Hölscher, C., Graham, S. F., & Green, B. D. (2018) · Metabolites · doi:10.3390/metabo8040069 · Cited by 29
“The main pathological hallmarks of AD are the accumulation of β-amyloid plaques and neurofibrillary tangles [2,3].”
BackgroundAnalysis of post-translational modifications in Alzheimer's disease by mass spectrometry
Kelley, A. R., Bach, S. B. H., & Perry, G. L. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.11.002 · Cited by 27
Boutajangout, A., Lindberg, H., Awwad, A., Paul, A., Baitalmal, R., Almokyad, I. K., Höidén‐Guthenberg, I., Gunneriusson, E., Frejd, F. Y., Härd, T., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00064 · Cited by 26
Martin-Estebane, M., & Gomez-Nicola, D. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00149 · Cited by 25
Yuan, Q., Su, H., Zhang, Y., Chau, W. H., Ng, C. T., Song, Y., Huang, J., Wu, W., & Lin, Z. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122323 · Cited by 29
“Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the presence of senile plaques, neurofibrillary tangles, and widespread neuronal loss in the brain of affected patients [1–3].”
Simone, A. D., Bartolini, M., Baschieri, A., Apperley, K. Y.-P., Chen, H. H., Guardigni, M., Montanari, S., Kobrlová, T., Soukup, O., Valgimigli, L., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.058 · Cited by 26
Alzheimer’s disease manifests abnormal sphingolipid metabolism
Uranbileg, B., Isago, H., Sakai, E., Kubota, M., Saito, Y., & Kurano, M. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1368839 · Cited by 30
Navale, G. R., Ahmed, I., Lim, M. H., & Ghosh, K. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401991 · Cited by 26
Modeling the Aggregation Propensity and Toxicity of Amyloid-β Variants
Tiwari, M. K., & Kepp, K. P. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150046 · Cited by 29
“central role in the disease [26–28].”
Aβ1-42-induced dysfunction in synchronized gamma oscillation during working memory
Bai, W., Xia, M., Liu, T., & Tian, X. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.04.003 · Cited by 25
Animal Models of Alzheimer’s Disease
Newman, M., Kretzschmar, D., Khan, I., Chen, M., Verdile, G., & Lardelli, M. T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00040-1 · Cited by 31
Shinohara, M., Koga, S., Konno, T., Nix, J., Shinohara, M., Aoki, N., Das, P., Parisi, J. E., Petersen, R. C., Rosenberry, T. L., et al. (2017) · Brain · doi:10.1093/brain/awx284 · Cited by 28
Sirtuins as Modifiers of Huntington's Disease (HD) Pathology
Neo, S. H., & Tang, B. L. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.013 · Cited by 25
Liu, W., Sun, F.-X., Wan, M., Jiang, F., Xiangyu, B. O., Lin, L., Tang, H., & Xu, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00969 · Cited by 27
“Aβ has been shown to aggregate and accumulate abnormally in the brain of AD patients, and extracellular amyloid plaques of Aβ peptides aggregation can trigger a cascade of pathologic events leading to nerve fiber entanglement and neuronal apoptosis (Hardy and Selkoe, 2002; Karran et al., 2011).”
BackgroundAdalbert, R., Milde, S., Durrant, C., Ando, K., Stygelbout, V., Yilmaz, Z., Gould, S., Brion, J.-P., & Coleman, M. P. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.03.033 · Cited by 24
“Previously, it was suggested that tau may lie downstream of APP/Ab or on a necessary pathway that converges onto a common, downstream target (Karran et al., 2011; Morris et al., 2011).”
Helal, M., Igel‐Egalon, A., Lakmeche, A., Mazzocco, P., Perrillat-Mercerot, A., Pujo-Menjouet, L., Rezaei, H., & Tine, L. M. (2018) · Journal of Mathematical Biology · doi:10.1007/s00285-018-1267-1 · Cited by 28
Alternative Targets to Fight Alzheimer’s Disease: Focus on Astrocytes
Valenza, M., Facchinetti, R., Menegoni, G., Steardo, L., & Scuderi, C. (2021) · Biomolecules · doi:10.3390/biom11040600 · Cited by 26
“The amyloid cascade hypothesis states that the progressive accumulation and oligomerization of Aβ42 creates diffuse plaques in the brain parenchyma, causing neuroinflammation and, later, neurofibrillary tangles (NFTs), ultimately leading to synaptic dysfunction or loss, and neuronal death [36,64].”
BackgroundFinding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration
Espay, A. J., Herrup, K., & Daly, T. P. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85538-9.00008-0 · Cited by 28
Intracerebral Nanoparticle Transport Facilitated by Alzheimer Pathology and Age
Tracy, G. C., Huang, K.-Y., Hong, Y.-T., Ding, S., Noblet, H. A., Lim, K. H., Kim, E. C., Chung, H. J., & Kong, H. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c03222 · Cited by 24
Kroker, K. S., Moreth, J., Kußmaul, L., Rast, G. F., & Rosenbrock, H. (2013) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.04.006 · Cited by 27
Sato, C., Turkoz, M., Dearborn, J. T., Wozniak, D. F., Kopan, R., & Hass, M. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048180 · Cited by 24
“Alzheimer’s Disease (AD) is an incurable progressive neurodegenerative disease characterized by synaptic dysfunction and subsequent neurodegeneration, a hallmark of which are aggregates of amyloid b (Ab) peptide (for a review see [1]).”
Background-Secretase Modulators: Can We Combine Potency with Safety?
Gijsen, H. J. M., & Mercken, M. H. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/295207 · Cited by 27
Self-citationBriggs, C. A., Schneider, C., Richardson, J. C., & Stutzmann, G. E. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.013 · Cited by 27
“However, the pathogenic mechanisms of Ab remain incompletely understood (Benilova et al., 2012; Castellani and Smith, 2011; Herrup, 2010; Karran et al., 2011; Spires-Jones and Knafo, 2012) and the fractured correlation between Ab deposits and cognitive dysfunction is perplexing (Arnold et al.”
BackgroundInfluentialKolinko, Y., Krakorová, K., Cendelín, J., Tonar, Z., & Králíčková, M. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0049 · Cited by 28
“It is also accompanied by the accumulation of amyloid-β (Aβ) in the brain parenchyma (Karran et al., 2011).”
BackgroundDieta mediterránea y sus efectos benéficos en la prevención de la enfermedad de Alzheimer
Miranda, A., Gómez-Gaete, C., & Sigrid Mennickent, C. (2017) · Revista médica de Chile · doi:10.4067/s0034-98872017000400010 · Cited by 46
Synthesis of heterocycles from arylacetonitriles: Powerful tools for medicinal chemists
Lindsay‐Scott, P. J., & Gallagher, P. T. (2017) · Tetrahedron Letters · doi:10.1016/j.tetlet.2017.05.089 · Cited by 25
Benseny‐Cases, N., Álvarez-Marimon, E., Castillo-Michel, H. A., Cotte, M., Falcon, C., & Cladera, J. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04818 · Cited by 26
The Amyloid Precursor Protein Controls PIKfyve Function
Balklava, Z., Niehage, C., Currinn, H., Mellor, L. E., Benjamin, G., Poulin, G. B., Hoflack, B., & Wassmer, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130485 · Cited by 31
“This raises the possibility that progression of Alzheimer's disease is driven by processes other than beta amyloid accumulation [39, 40].”
BackgroundHochard, A., Oumata, N., Bettayeb, K., Gloulou, O., Fant, X., Durieu, É., Buron, N., Porceddu, M., Borgne‐Sanchez, A., Galons, H., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121777 · Cited by 29
Meghdadi, A. H., Salat, D. H., Hamilton, J. M., Hong, Y., Boeve, B. F., Louis, E. K. S., Verma, A. K., & Berka, C. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308137 · Cited by 32
Gibson, A. W., Elser, H. C., Rosso, M., Cornblath, E. J., Fonkeu, Y., Prasad, S., Rothstein, A., Nasrallah, I. M., Wolk, D. A., & Guo, M. H. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14223 · Cited by 23
Efficient amyloid-β degradation in Alzheimer’s disease using SPYTACs
Teng, F., Liu, J., Cui, T., Tan, X., Liu, K., Hou, Z., (54356), L. Z., Xie, Y., Li, R., Li, D., et al. (2026) · Cell · doi:10.1016/j.cell.2026.01.034 · Cited by 31
Wallace, J. (2014) · Cell Calcium · doi:10.1016/j.ceca.2014.02.005 · Cited by 24
Diomede, L., Romeo, M., Cagnotto, A., Rossi, A., Beeg, M., Stravalaci, M., Tagliavini, F., Fede, G. D., Gobbi, M., & Salmona, M. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.01.006 · Cited by 23
Whole‐brain DTI parameters associated with tau protein and hippocampal volume in Alzheimer's disease
Magalhães, T. N. C., Casseb, R. F., Gerbelli, C. L. B., Pimentel‐Siva, L. R., Nogueira, M. H., Teixeira, C. V. L., Carletti, A. F. M. K., de Rezende, T. J. R., Joaquim, H. P. G., Talib, L. L., et al. (2023) · Brain and Behavior · doi:10.1002/brb3.2863 · Cited by 16
Metadata
- Authors
- Karran, E., Mercken, M., & Strooper, B. D.
- Affiliations
- Janssen (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Karran, Eric
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-19
- Volume
- 10
- Issue
- 9
- Pages
- 698-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2079749054
- Cited by
- 2,188
- References
- 157
- Citations by year
- 2026: 74 · 2025: 115 · 2024: 130 · 2023: 139 · 2022: 141 · 2021: 158 · 2020: 174 · 2019: 191 · 2018: 174 · 2017: 163 · 2016: 171 · 2015: 160 · 2014: 151 · 2013: 130 · 2012: 107
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid hypothesis, Alzheimer's disease, amyloid-beta, amyloid-beta aggregation, amyloid-beta production, clinical trial design, phase III trial failure, drug development
- MeSH terms
- Alzheimer Disease, Animals, Brain Chemistry, Humans, Research Design, Amyloid beta-Peptides, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Age of Onset, Disease Progression, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.